GLP-1 · Dual GIP/GLP-1 agonist · weekly · strong appetite suppression
Tirzepatide
Tirzepatide is a dual GIP and GLP-1 receptor agonist with more aggressive weight-loss outcomes than pure GLP-1 agonists. Titrate every 4 weeks.
Vial sizes
10 mg · 15 mg · 30 mg · 60 mg
Recommended BAC water
2 mL
Stable refrigerated
42 days
Titration schedule
| When | Dose | Units @ 5.0 mg/mL |
|---|---|---|
| Weeks 1–4 | 2.5 mg / week | 50.0 units |
| Weeks 5–8 | 5.0 mg / week | 100.0 units |
| Weeks 9–12 | 7.5 mg / week | 150.0 units |
| Weeks 13–16 | 10 mg / week | 200.0 units |
| Weeks 17–20 | 12.5 mg / week | 250.0 units |
| Week 21+ | 15 mg / week (max) | 300.0 units |
Reconstitution example
For a 10 mg vial + 2 mL BAC water
Concentration
5.00 mg/mL
Per 0.1 mL (10 units)
0.50 mg
Doses per vial (avg)
1.0
What to watch for
- Side effects are dose-dependent — many users hold at 5 or 7.5 mg long-term.
- Most efficient water ratio for a 10 mg vial is 1–2 mL.
- Pair with adequate protein (>0.7 g/lb) to protect lean mass during weight loss.
Educational summary, not medical advice. Cross-reference current clinical literature and consult a licensed clinician before use.